CLOBENZOREX

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H18ClN
Molecular Weight	259.774
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

C[C@@H](CC1=CC=CC=C1)NCC2=CC=CC=C2Cl

InChI

InChIKey=LRXXRIXDSAEIOR-ZDUSSCGKSA-N

InChI=1S/C16H18ClN/c1-13(11-14-7-3-2-4-8-14)18-12-15-9-5-6-10-16(15)17/h2-10,13,18H,11-12H2,1H3/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C16H18ClN
Molecular Weight	259.774
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Clobenzorex is a central stimulant and sympathomimetic used as an anti-obesity drug; an n-substituted amphetamine, which is metabolized to amphethamine. Its actions are like those of dexamphetamine and has been used as a drug of abuse.

CNS Activity

Approval Year

Conditions

Conditions

Condition	Modality	Targets	Highest Phase	Product
Obesity 203	Primary		Approved 8,429	ASENLIX

C_max

Value	Dose	Co-administered	Analyte	Population
1.777 ng/mL	60 mg single, oral		CLOBENZOREX plasma	Homo sapiens
3.429 ng/mL	30 mg single, oral		CLOBENZOREX plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
17.777 ng × h/mL	60 mg single, oral		CLOBENZOREX plasma	Homo sapiens
11.076 ng × h/mL	30 mg single, oral		CLOBENZOREX plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
15.002 h	60 mg single, oral		CLOBENZOREX plasma	Homo sapiens
3.118 h	30 mg single, oral		CLOBENZOREX plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
210 mg 3 times / day multiple, oral Higher than recommended	unhealthy, ADULT	Disc. AE: Congestive cardiomyopathy...
90 mg single, oral Highest studied dose	unhealthy, ADULT

Showing 1 to 2 of 2 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Congestive cardiomyopathy	Disc. AE	210 mg 3 times / day multiple, oral Higher than recommended	unhealthy, ADULT

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Role of substance P on histamine H(3) antagonist-induced scratching behavior in mice.	2006 Apr	16603804
Benfluorex and unexplained valvular heart disease: a case-control study.	2010 Apr 12	20405030
Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.	2010 Mar	20233200

Showing 1 to 3 of 3 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

30 mg bid.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical
Record UNII	4A5352XI2A
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

CLOBENZOREX

Official Name

English

BENZENEETHANAMINE, N-((2-CHLOROPHENYL)METHYL)-.ALPHA.-METHYL-, (S)-

Systematic Name

English

Clobenzorex [WHO-DD]

Common Name

English

SD-271-12

Code

English

clobenzorex [INN]

Common Name

English

Showing 1 to 5 of 10 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Centrally acting antiobesity products

WHO-VATC

QA08AA08

Agent Affecting Nervous System

NCI_THESAURUS

C29728

Centrally acting antiobesity products

WHO-ATC

A08AA08

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

ECHA (EC/EINECS)

236-434-4

PRIMARY

WIKIPEDIA

CLOBENZOREX

PRIMARY

DRUG CENTRAL

684

PRIMARY

SMS_ID

100000084281

PRIMARY

NCI_THESAURUS

C77327

PRIMARY

Showing 1 to 5 of 16 entries

Previous1 2 3 4Next

Show entries

Related Record

Type

Details


					BC6X5MB664

CLOBENZOREX HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					4A5352XI2A

CLOBENZOREX

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

CNS Activity

Approval Year

Conditions

Cmax

AUC

T1/2

Doses

AEs

PubMed

Patents

Sample Use Guides

C_max

T_1/2